233755-50-5Relevant academic research and scientific papers
CoIII-Catalyzed Isonitrile Insertion/Acyl Group Migration Between C?H and N?H bonds of Arylamides
Kalsi, Deepti,Barsu, Nagaraju,Sundararaju, Basker
supporting information, p. 2360 - 2364 (2018/02/22)
A general efficient and site-selective cobalt-catalyzed insertion of isonitrile into C?H and N?H bonds of arylamides through C?H bond activation and alcohol assisted intramolecular trans-amidation is demonstrated. This straightforward approach overcomes the limitation by the presence of strongly chelating groups. Isolation of CoIII-isonitrile complex B has been achieved for the first time to understand the reaction mechanism.
Ruthenium-Catalyzed Difluoroalkylation of 8-Aminoquinoline Amides at the C5-Position
Chen, Changpeng,Zeng, Runsheng,Zhang, Jingyu,Zhao, Yingsheng
supporting information, p. 6947 - 6950 (2017/12/26)
A ruthenium-catalyzed highly selective difluoromethylation of 8-aminoquinoline amides at the C5 position has been developed. It tolerates a broad range of functional groups, providing the corresponding difluoromethylated products in moderate to good yields. Preliminary experimental results indicate that the tricoordinate ruthenium intermediate is the key factor in achieving the C5-position selectivity.
PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS
-
Page/Page column 41, (2008/12/05)
The present invention is concerned with novel piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to
2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
-
Page 68, (2010/02/07)
Compounds having formula (1) are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.
2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
-
, (2008/06/13)
Compounds having the following formula: ? are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
-
, (2008/06/13)
Compounds are provided having the following formula: wherein R, R1, R2, R3, and R4 are defined in the specification, which have matrix metalloproteinase inhibiting activity.
